Literature DB >> 5220233

Toxicology studies in patients on prolonged therapy with capreomycin.

J D Miller, A G Popplewell, A Landwehr, M E Greene.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 5220233     DOI： 10.1111/j.1749-6632.1966.tb45545.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  7 in total

1.  [Clinical experiences with the tuberculostatic drug capreomycin].

Authors:  H Kollmeier; E Winkler; H Voss; M Ilgner
Journal:  Beitr Klin Erforsch Tuberk Lungenkr       Date:  1968

2.  Capreomycin-induced serum electrolyte abnormalities.

Authors:  A M Holmes; C M Hesling; T M Wilson
Journal:  Thorax       Date:  1970-09       Impact factor: 9.139

3.  [Personal experiences with capreomycin].

Authors:  C Virchow
Journal:  Beitr Klin Erforsch Tuberk Lungenkr       Date:  1967

4.  [Intravenous infusion of capreomycin].

Authors:  R Kropp; I Dücker; H Jungbluth
Journal:  Pneumonologie       Date:  1971

5.  Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.

Authors:  Amber Arnold; Graham S Cooke; Onn Min Kon; Martin Dedicoat; Marc Lipman; Angela Loyse; Irina Chis Ster; Thomas S Harrison
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.

Authors:  L Garcia-Contreras; Pavan Muttil; John K Fallon; Mohan Kabadi; Robert Gerety; Anthony J Hickey
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

Review 7.  Ototoxicity of Non-aminoglycoside Antibiotics.

Authors:  Leonard P Rybak; Vickram Ramkumar; Debashree Mukherjea
Journal:  Front Neurol       Date:  2021-03-09       Impact factor: 4.003
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.